USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia

Constitutive activation of tyrosine kinase Bcr-Abl is the leading cause of the development and progression of chronic myeloid leukemia (CML). Currently, the application of tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl is the primary therapy for CML patients. However, acquired resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Yuning, Liu, Ningning, Xia, Xiaohong, Guo, Zhiqiang, Li, Yanling, Jiang, Lili, Zhou, Ruiqing, Tang, Daolin, Huang, Hongbiao, Liu, Jinbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488640/
https://www.ncbi.nlm.nih.gov/pubmed/31044085
http://dx.doi.org/10.1038/s41421-019-0092-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488640/
https://www.ncbi.nlm.nih.gov/pubmed/31044085
http://dx.doi.org/10.1038/s41421-019-0092-z

Ejemplares similares